Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report

Abstract Background Hydroxychloroquine and chloroquine have been used for hospitalized coronavirus disease 2019 patients because of their antiviral and anti-inflammatory function. However, little research has been published on the impact of the immunomodulatory effect of (hydroxy)chloroquine on humo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Astrid Muyldermans, Piet Maes, Tony Wawina-Bokalanga, Tine Anthierens, Olivier Goldberg, Magali Bartiaux, Oriane Soetens, Ingrid Wybo, Sigi Van den Wijngaert, Denis Piérard
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	SARS-CoV-2 COVID-19 Reinfection Hydroxychloroquine Lupus Case report Medicine R
Acceso en línea:	https://doaj.org/article/080113d2b6d1464dbdc08455fc51a929
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:080113d2b6d1464dbdc08455fc51a929
record_format	dspace
spelling	oai:doaj.org-article:080113d2b6d1464dbdc08455fc51a9292021-11-28T12:37:14ZSymptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report10.1186/s13256-021-03159-91752-1947https://doaj.org/article/080113d2b6d1464dbdc08455fc51a9292021-11-01T00:00:00Zhttps://doi.org/10.1186/s13256-021-03159-9https://doaj.org/toc/1752-1947Abstract Background Hydroxychloroquine and chloroquine have been used for hospitalized coronavirus disease 2019 patients because of their antiviral and anti-inflammatory function. However, little research has been published on the impact of the immunomodulatory effect of (hydroxy)chloroquine on humoral immunity. Case presentation We report a case of symptomatic severe acute respiratory syndrome coronavirus 2 reinfection, diagnosed 141 days after the first episode, in a 56-year-old man of Black African origin treated with hydroxychloroquine for lupus erythematosus. No anti-severe acute respiratory syndrome coronavirus 2 IgG antibodies could be detected 127 days after the initial episode of coronavirus disease 2019. Conclusions The treatment with hydroxychloroquine probably explains the decreased immune response with negative serology and subsequent reinfection in our patient. As humoral immunity is crucial to fight a severe acute respiratory syndrome coronavirus 2 infection, the use of (hydroxy)chloroquine is likely to have a detrimental effect on the spread of the virus. This case emphasizes that more needs to be learned about the role of antibodies in protecting against severe acute respiratory syndrome coronavirus 2 (re)infection and the role of (hydroxy)chloroquine on humoral immunity.Astrid MuyldermansPiet MaesTony Wawina-BokalangaTine AnthierensOlivier GoldbergMagali BartiauxOriane SoetensIngrid WyboSigi Van den WijngaertDenis PiérardBMCarticleSARS-CoV-2COVID-19ReinfectionHydroxychloroquineLupusCase reportMedicineRENJournal of Medical Case Reports, Vol 15, Iss 1, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 Reinfection Hydroxychloroquine Lupus Case report Medicine R
spellingShingle	SARS-CoV-2 COVID-19 Reinfection Hydroxychloroquine Lupus Case report Medicine R Astrid Muyldermans Piet Maes Tony Wawina-Bokalanga Tine Anthierens Olivier Goldberg Magali Bartiaux Oriane Soetens Ingrid Wybo Sigi Van den Wijngaert Denis Piérard Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
description	Abstract Background Hydroxychloroquine and chloroquine have been used for hospitalized coronavirus disease 2019 patients because of their antiviral and anti-inflammatory function. However, little research has been published on the impact of the immunomodulatory effect of (hydroxy)chloroquine on humoral immunity. Case presentation We report a case of symptomatic severe acute respiratory syndrome coronavirus 2 reinfection, diagnosed 141 days after the first episode, in a 56-year-old man of Black African origin treated with hydroxychloroquine for lupus erythematosus. No anti-severe acute respiratory syndrome coronavirus 2 IgG antibodies could be detected 127 days after the initial episode of coronavirus disease 2019. Conclusions The treatment with hydroxychloroquine probably explains the decreased immune response with negative serology and subsequent reinfection in our patient. As humoral immunity is crucial to fight a severe acute respiratory syndrome coronavirus 2 infection, the use of (hydroxy)chloroquine is likely to have a detrimental effect on the spread of the virus. This case emphasizes that more needs to be learned about the role of antibodies in protecting against severe acute respiratory syndrome coronavirus 2 (re)infection and the role of (hydroxy)chloroquine on humoral immunity.
format	article
author	Astrid Muyldermans Piet Maes Tony Wawina-Bokalanga Tine Anthierens Olivier Goldberg Magali Bartiaux Oriane Soetens Ingrid Wybo Sigi Van den Wijngaert Denis Piérard
author_facet	Astrid Muyldermans Piet Maes Tony Wawina-Bokalanga Tine Anthierens Olivier Goldberg Magali Bartiaux Oriane Soetens Ingrid Wybo Sigi Van den Wijngaert Denis Piérard
author_sort	Astrid Muyldermans
title	Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
title_short	Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
title_full	Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
title_fullStr	Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
title_full_unstemmed	Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
title_sort	symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report
publisher	BMC
publishDate	2021
url	https://doaj.org/article/080113d2b6d1464dbdc08455fc51a929
work_keys_str_mv	AT astridmuyldermans symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT pietmaes symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT tonywawinabokalanga symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT tineanthierens symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT oliviergoldberg symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT magalibartiaux symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT orianesoetens symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT ingridwybo symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT sigivandenwijngaert symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport AT denispierard symptomaticsevereacuterespiratorysyndromecoronavirus2reinfectioninalupuspatienttreatedwithhydroxychloroquineacasereport
_version_	1718407873787068416

Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report

Ejemplares similares